TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K

What Happened
Teva Pharmaceutical Industries Ltd. held its Annual Meeting on May 28, 2026 and reported the shareholder voting results in an 8-K filing. Shareholders elected Dr. Sol J. Barer to the Board to serve until Teva’s 2029 annual meeting. Shareholders also approved, on a non-binding advisory basis, the compensation of named executive officers (say-on-pay), and approved the appointment of Kesselman & Kesselman (a PwC member firm) as Teva’s independent registered public accounting firm until the 2027 annual meeting.

Key Details

• Director election (term to 2029): Dr. Sol J. Barer — For 627,816,662; Against 245,921,571; Abstain 530,682; Broker non-votes 50,661,570 (≈71.8% FOR of votes cast).
• Advisory vote on executive compensation (non‑binding): For 795,976,042; Against 77,082,847; Abstain 1,170,026; Broker non-votes 50,661,570 (≈91.0% FOR of votes cast).
• Auditor appointment (until 2027 meeting): Kesselman & Kesselman — For 880,542,242; Against 36,085,507; Abstain 525,382; Broker non-votes 0 (≈96.0% FOR of votes cast).

Why It Matters
These results confirm board composition and governance choices ratified by shareholders. The strong advisory approval of executive compensation signals broad investor support for the company’s pay practices (though the vote is non-binding). The auditor appointment provides continuity for Teva’s external financial reporting through the next annual meeting. Investors can use these vote totals (including the 50.7M broker non‑votes reported on the contested items) as indicators of shareholder sentiment on governance and pay.